Timing of New Black Box Warnings and Withdrawals for Prescription Medications

Karen E. Lasser; Paul D. Allen; Steffie J. Woolhandler; et al.


http://jama.ama-assn.org/cgi/content/full/287/17/2215

Correction
Contact me if this article is corrected.

Citations
This article has been cited 241 times.
Contact me when this article is cited.

Topic collections
Drug Therapy; Adverse Effects; Drug Therapy, Other
Contact me when new articles are published in these topic areas.

Related Articles published in the same issue
Safety of Newly Approved Drugs: Implications for Prescribing

May 1, 2002
JAMA. 2002;287(17):2295.

Related Letters
Postprandial Hyperglycemia and Risk of Atherosclerosis

Postmarketing Surveillance and Black Box Warnings
Original Contribution

Timing of New Black Box Warnings and Withdrawals for Prescription Medications

Karen E. Lasser, MD, MPH
Paul D. Allen, MD, MPH
Steffie J. Woolhandler, MD, MPH
David U. Himmelstein, MD
Sidney M. Wolfe, MD
David H. Bor, MD

Adverse drug reactions (ADRs) are believed to be a leading cause of death in the United States. Prior to approval, drugs are studied in selected populations for limited periods, possibly contributing to an increased risk of ADRs after approval. Pharmaceutical companies frequently market new drugs heavily to both patients and clinicians before the full range of ADRs is ascertained. Inadequate clinician reporting may delay detection of postmarketing ADRs; less than 10% of all ADRs are estimated to be reported to MEDWATCH, the Food and Drug Administration’s (FDA’s) voluntary postmarketing reporting system.

Patient exposure to new drugs with unknown toxic effects may be extensive. Nearly 20 million patients in the United States took at least 1 of the 5 drugs withdrawn from the market between September 1997 and September 1998. Three of these 5 drugs were new, having been on the market for less than 2 years. Seven drugs approved since 1993 and subsequently withdrawn from the market have been reported as possibly contributing to 1002 deaths. For example, cisapride was approved for the treatment of a benign condition, nocturnal gastrointestinal reflux in adults. After its introduction, many pediatricians prescribed the drug to infants with gastric reflux, 24 of whom were reported to have died.

Should clinicians hesitate to prescribe newly approved drugs? Few data are available on how frequently serious ADRs are discovered after drug introduction. Previous studies examining drug labeling changes have found high rates of undetected postapproval risks with low rates of subsequent drug withdrawal. However, no study has analyzed changes in the Physicians’ Desk Reference, the most commonly used source of labeling information. We analyzed the incidence of new black box warnings in the Physicians’ Desk Reference from 1975 to 2000, a marker of the most serious ADRs, and used survival analyses to determine the course of their discovery. We also calculated the frequency and timing of drug withdrawals over this period.

Methods

Data Sources and Definitions

We chose the study period 1975-2000 because it corresponds with the FDA’s

Context

Recently approved drugs may be more likely to have unrecognized adverse drug reactions (ADRs) than established drugs, but no recent studies have examined how frequently postmarketing surveillance identifies important ADRs.

Objective

To determine the frequency and timing of discovery of new ADRs described in black box warnings or necessitating withdrawal of the drug from the market.

Design and Setting

Examination of the Physicians’ Desk Reference for all new chemical entities approved by the US Food and Drug Administration between 1975 and 1999, and all drugs withdrawn from the market between 1975 and 2000 (with or without a prior black box warning).

Main Outcome Measures

Frequency of and time to a new black box warning or drug withdrawal.

Results

A total of 548 new chemical entities were approved in 1975-1999; 56 (10.2%) acquired a new black box warning or were withdrawn. Forty-five drugs (8.2%) acquired 1 or more black box warnings and 16 (2.9%) were withdrawn from the market. In Kaplan-Meier analyses, the estimated probability of acquiring a new black box warning or being withdrawn from the market over 25 years was 20%. Eighty-one major changes to drug labeling in the Physicians’ Desk Reference occurred including the addition of 1 or more black box warnings per drug, or drug withdrawal. In Kaplan-Meier analyses, half of these changes occurred within 7 years of drug introduction; half of the withdrawals occurred within 2 years.

Conclusions

Serious ADRs commonly emerge after Food and Drug Administration approval. The safety of new agents cannot be known with certainty until a drug has been on the market for many years.

JAMA. 2002;287:2215-2220

For editorial comment see p 2273.

©2002 American Medical Association. All rights reserved.
modern era of drug surveillance.\textsuperscript{37,38} We obtained a list of drugs approved from 1975-1999 from the Tufts Center for the Study of Drug Development.\textsuperscript{39} (Drugs approved in 2000 were excluded because none appear in the other data source for the study, the year 2000 Physicians’ Desk Reference,\textsuperscript{40} which was released in November 1999.) We used the drug approval date to approximate the date the drug was first marketed. We compiled a list of drugs withdrawn for safety reasons from a Federal Register notice\textsuperscript{41} published in 1998 and from information on the FDA Web site about drug withdrawals between 1998 and 2000.\textsuperscript{42-44} We defined a drug as “withdrawn for safety reasons” if the drug removal was initiated by the FDA for safety reasons or if the manufacturer voluntarily withdrew it from the market following the identification of life-threatening ADRs.

We included all drugs that the FDA defined as new molecular entities (ie, an active ingredient that had never been marketed in the United States).\textsuperscript{45} We excluded over-the-counter medications, diagnostic agents, and biologics (defined as any drug approved through the FDA’s Center for Biologics Evaluation and Research\textsuperscript{46}). We included drugs initially available by prescription that subsequently became available over-the-counter (eg, cimetidine).

We identified black box warnings through a manual search of all 26 annual volumes of the Physicians’ Desk Reference between 1975 and 2000.\textsuperscript{10,35} The Physicians’ Desk Reference, an annual compendium of the FDA-approved professional product labeling for selected drugs, is released in November of the year before its cover date. Black box warnings are prominently displayed in the Physicians’ Desk Reference to alert practitioners to serious risks.\textsuperscript{46} According to the Federal Register,

Special problems, particularly those that may lead to death or serious injury, may be required by the Food and Drug Administration to be placed in a prominently displayed box. The boxed warning ordinarily shall be based on clinical data, but serious animal toxicity may also be the basis of a boxed warning in the absence of clinical data.\textsuperscript{47}

We excluded black box warnings that were present when a drug first appeared in the Physicians’ Desk Reference. We also excluded black box warnings that a drug should be administered by a qualified physician, as this warning may not indicate a new ADR. We defined a Physicians’ Desk Reference change as either the addition of 1 or more black box warnings per drug or the withdrawal of a drug.

Analysis

For drugs that had a black box warning in the 2000 Physicians’ Desk Reference, we examined earlier editions of the Physicians’ Desk Reference to determine when the black box warning first appeared. If a drug did not have a black box warning in the Physicians’ Desk Reference in which it first appeared, we measured the time (rounded to the nearest month) that elapsed between the approval date and the year of the first Physicians’ Desk Reference in which a black box warning appeared. We approximated the exact date of the Physicians’ Desk Reference year as January 1 of its cover year. We similarly measured the time from approval to withdrawal for drugs withdrawn for safety reasons.

We calculated the proportion of all new drugs that acquired a new black box warning or withdrawal from the market for safety reasons. For drugs that acquired multiple black box warnings, we counted each warning as a separate event. For withdrawn drugs that had a black box warning prior to withdrawal, we counted 2 separate events in the analysis of Physicians’ Desk Reference changes, and counted only the withdrawal date in the analysis of time until withdrawal. We calculated the time that elapsed before 50% of eventual drug withdrawals took place, and the time that elapsed before 50% of all Physicians’ Desk Reference changes were made. We also analyzed the content of the black box warnings and the reasons for withdrawal according to the type of toxicity.

Statistical Methods

We used the SAS statistical package (Version 8; SAS Institute, Cary, NC) for frequency analysis, and the Lifetests procedure to calculate Kaplan-Meier survival curves for censored failure-time data. We used Kaplan-Meier survival curves to estimate a drug’s “survival” (without reaching the end point of a new black box warning and/or withdrawal from the market) over the study period, taking into account the fact that drugs are on the market for varying periods (some briefly). We censored those drugs that had not reached the end point in question at the time of the analysis.

RESULTS

Five hundred forty-eight new chemical entities were approved from 1975-1999. Of these, 56 (10.2%) drugs acquired a new black box warning or were withdrawn from the market. In Kaplan-Meier analyses, the estimated probability of a new drug acquiring black box warnings or being withdrawn from the market over 25 years was 20% (FIGURE). Forty-five drugs (8.2%) acquired 1 or more black box warnings that were not present when the drug was approved (TABLE 1). Sixteen drugs (2.9%) approved between 1975 and 2000 were withdrawn from the market between 1975 and 2000; 5 had acquired a black box warning prior to withdrawal (TABLE 2). In Kaplan-Meier analyses, new drugs had a 4% probability of being withdrawn from the market over the study period. Half of withdrawals occurred within 2 years following the drug’s introduction. There were 81 changes in the Physicians’ Desk Refer-
Table 1. Drugs With a New Black Box Warning, 1975-2000*

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Food and Drug Administration Class</th>
<th>Drug Approval Date</th>
<th>Warning</th>
<th>Time to First Physicians’ Desk Reference Black Box Warning in Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pemoline</td>
<td>Central nervous system stimulant</td>
<td>January 27, 1975</td>
<td>Hepatic toxicity</td>
<td>22.9</td>
</tr>
<tr>
<td>Dacarbazine†</td>
<td>Antineoplastic</td>
<td>May 27, 1975</td>
<td>Hepatic toxicity</td>
<td>4.6</td>
</tr>
<tr>
<td>Danazol</td>
<td>Infertility</td>
<td>June 21, 1976</td>
<td>Unsafe during pregnancy, Pseudotumor cerebri, Peliosis hepatis, Thrombotic events and strokes</td>
<td>15.5</td>
</tr>
<tr>
<td>Lomustine</td>
<td>Antineoplastic</td>
<td>August 4, 1976</td>
<td>Bone marrow toxicity</td>
<td>1.4</td>
</tr>
<tr>
<td>Carmustine†</td>
<td>Antineoplastic</td>
<td>March 3, 1977</td>
<td>Pulmonary fibrosis</td>
<td>4.8</td>
</tr>
<tr>
<td>Disopyramide phosphate</td>
<td>Antiarrhythmic</td>
<td>August 31, 1977</td>
<td>Increased mortality with class IC antiarrhythmics</td>
<td>19.3</td>
</tr>
<tr>
<td>Valproate sodium</td>
<td>Anticonvulsant</td>
<td>February 28, 1978</td>
<td>Hepatic toxicity</td>
<td>3.8</td>
</tr>
<tr>
<td>Metoprolol</td>
<td>Antianginal, antihypertensive β-blocker</td>
<td>August 7, 1978</td>
<td>Exacerbation of coronary artery disease when drug discontinued</td>
<td>6.4</td>
</tr>
<tr>
<td>Captopril</td>
<td>Antihypertensive ACE inhibitor</td>
<td>April 6, 1981</td>
<td>Unsafe during pregnancy</td>
<td>11.7</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>Antifungal</td>
<td>June 12, 1981</td>
<td>Hepatic toxicity, Cardiotoxic if used with terfenadine, Astemizole, Cisapride</td>
<td>12.6, 2.6, 15.6, 11.6</td>
</tr>
<tr>
<td>Atenolol</td>
<td>Antianginal, antihypertensive β-blocker</td>
<td>August 19, 1981</td>
<td>Exacerbation of coronary artery disease when drug discontinued</td>
<td>5.4</td>
</tr>
<tr>
<td>Isotretinoin</td>
<td>Dermatologic (acne)</td>
<td>May 27, 1982</td>
<td>Unsafe during pregnancy, Pseudotumor cerebri, Hypertension (Neoral), Nephrototoxicity (Neoral)</td>
<td>2.6, 2.6, 14.2, 14.2</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Immunomodulator</td>
<td>November 14, 1983</td>
<td>Immunosuppression, Hypertension (Neoral)</td>
<td>1.2, 14.2</td>
</tr>
<tr>
<td>Tocainide hydrochloride</td>
<td>Antiarrhythmic</td>
<td>November 9, 1984</td>
<td>Pulmonary fibrosis, Bone marrow toxicity</td>
<td>4.2, 5.2</td>
</tr>
<tr>
<td>Terfenadine§</td>
<td>Antihistamine</td>
<td>May 8, 1985</td>
<td>Drug interactions causing cardiotoxicity</td>
<td>8.7</td>
</tr>
<tr>
<td>Mexiletine hydrochloride</td>
<td>Antiarrhythmic</td>
<td>May 16, 1985</td>
<td>Increased mortality with class IC antiarrhythmics</td>
<td>13.0</td>
</tr>
<tr>
<td>Plicainide acetate</td>
<td>Antiarrhythmic</td>
<td>October 31, 1985</td>
<td>Increased mortality in patients with asymptomatic ventricular arrhythmias</td>
<td>3.2</td>
</tr>
<tr>
<td>Midazolam hydrochloride</td>
<td>Adjunct to anesthesia</td>
<td>December 20, 1985</td>
<td>Respiratory depression</td>
<td>3.0</td>
</tr>
<tr>
<td>Enalapril maleate</td>
<td>Antihypertensive ACE inhibitor</td>
<td>December 24, 1985</td>
<td>Unsafe during pregnancy</td>
<td>7.0</td>
</tr>
<tr>
<td>Ribavirin†</td>
<td>Antiviral</td>
<td>December 31, 1985</td>
<td>Increase in pulmonary artery pressures</td>
<td>8.0</td>
</tr>
<tr>
<td>Encainide hydrochloride§</td>
<td>Antiarrhythmic</td>
<td>December 24, 1986</td>
<td>Increased mortality in patients with asymptomatic ventricular arrhythmias</td>
<td>3.0</td>
</tr>
<tr>
<td>Zidovudine†</td>
<td>Antiviral</td>
<td>March 19, 1987</td>
<td>Hepatomegaly, Lactic acidosis, Myopathy</td>
<td>7.8, 7.8, 7.8</td>
</tr>
<tr>
<td>Mitoxantrone hydrochloride</td>
<td>Antineoplastic</td>
<td>December 23, 1987</td>
<td>Bone marrow toxicity</td>
<td>10.0</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>Antihypertensive ACE inhibitor</td>
<td>December 29, 1987</td>
<td>Unsafe during pregnancy</td>
<td>5.0</td>
</tr>
<tr>
<td>Astemizole§</td>
<td>Antihistamine</td>
<td>December 29, 1988</td>
<td>Drug interactions causing cardiotoxicity</td>
<td>4.0</td>
</tr>
<tr>
<td>Ganciclovir†</td>
<td>Antiviral</td>
<td>June 23, 1989</td>
<td>Oral form not as effective as intravenous</td>
<td>6.5</td>
</tr>
<tr>
<td>Clozapine†</td>
<td>Antipsychotic, antimanic</td>
<td>September 26, 1989</td>
<td>Hypotension</td>
<td>3.2</td>
</tr>
<tr>
<td>Propafenone hydrochloride</td>
<td>Antiarrhythmic</td>
<td>November 1, 1989</td>
<td>Increased mortality with class IC antiarrhythmics</td>
<td>9.2</td>
</tr>
<tr>
<td>Ketorolac tromethamine</td>
<td>Analgesic, nonsteroidal anti-inflammatory</td>
<td>November 30, 1989</td>
<td>Gastrointestinal tract bleeding, Adjust dose in renal failure, Hypersensitivity, Not for intrathecal/epidural use</td>
<td>6.1, 6.1, 6.1, 6.1, 6.1</td>
</tr>
</tbody>
</table>

*Continued*
ence during the study period. In Kaplan-Meier analyses, 50% of these changes occurred within 7 years following drug introduction. Physicians' Desk Reference changes were most commonly made for hepatic toxicity (n=15 [19%]), hematologic toxicity (n=13 [16%]), cardiovascular toxicity (n=17 [21%]), and risk in pregnancy (n=9 [11%]).

We noted several inconsistencies among Physicians' Desk Reference safety warnings. The Physicians' Desk Reference entries for the β-blockers timolol maleate, atenolol, and metoprolol contained black box warnings indicating that abrupt discontinuation of the drug could exacerbate coronary artery disease. However, the entries for the β-blockers carteolol hydrochloride, penbutolol sulfate, and bisoprolol fumarate had no such warning. We also observed asynchro-

ous appearances of black box warnings among drugs of the same class. Timolol obtained a black box warning in 1983, while metoprolol and atenolol obtained the same warning in 1985 and 1987, respectively. Similarly, the combination drug triamterene-hydrochlorothiazide obtained a black box warning for hyperkalemia in 1989, while triamterene obtained this warning in 1981. Finally, ketoconazole obtained a black box warning for a life-threatening drug interaction with terfenadine in the 1993 Physicians' Desk Reference, while terfenadine did not have a comparable warning until 1994.

### COMMENT

Many serious ADRs are discovered only after a drug has been on the market for years. Only half of newly discovered serious ADRs are detected and documented in the Physicians' Desk Reference within 7 years after drug approval. Our definition of a serious ADR was conservative, since it was limited to Physicians' Desk Reference black box warnings. We did not consider other labeling changes such as bolded warnings without boxes, “Dear Health Care Professional” letters, or case reports in the medical literature. Our finding that half of all drug withdrawals occurred within 2 years is consistent with previous research, as is our documentation of potentially dangerous inconsistencies in the Physicians' Desk Reference.48-50

Why are so many ADRs brought to light only after drug approval? Premarketing drug trials are often underpowered to detect ADRs, and have limited follow-up. In some cases, drugs are
approved despite identification of serious ADRs in premarketing trials. For instance, alosetron hydrochloride was reported to be associated with ischemic colitis prior to its approval, and grepafloxacin hydrochloride was approved despite reports of QT prolongation and 2 possible deaths. Both were subsequently withdrawn from the market because of these adverse events. Some drugs represent a significant advance over existing drugs in the reduction of morbidity and mortality and warrant use despite limited experience. However, the drugs that do not represent a significant advance should be considered second-line drugs until their safety profile is better known.

Despite limited knowledge about the safety of new drugs, their market uptake and sales volume may be explosive. The pharmaceutical industry promotes the early use of new drugs, and influences physicians’ adoption of such drugs. Direct-to-consumer drug advertising also generates a high volume of new drug prescriptions. Drug firms may rush new drugs to market because of concerns about patent life, a desire to mold prescribing habits prior to the market entry of competitors, and hopes for a fast “ramp-up” in sales that will encourage investors and increase stock prices. New drug safety may be further compromised by the apparent failure by drug companies to conduct postmarketing (phase 4) studies, which are required by the FDA when a safety question arises during the preapproval period.

Given the frequent introduction of drugs for which new serious adverse events are discovered, the FDA should consider raising its threshold for approving new drugs when safe, effective therapies already exist, or when the new drug treats a benign condition. Postmarketing surveillance should be completed, analyzed, and disseminated to physicians. The date of drug approval should be prominently included in drug labeling, and changes in labeling should be highlighted and dated. Furthermore, when a serious ADR is discovered, labeling of all drugs in the same class should be reviewed if a class effect is suspected.

Based on our results and those of others, clinicians should avoid using new drugs when older, similarly efficacious agents are available. Patients who must use new drugs should be informed of the drug’s limited experience and safety record, and be observed for possible he-

Table 2. Drugs Withdrawn From the Market for Safety Reasons, 1975–2000*

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Food and Drug Administration Class</th>
<th>Drug Approval Date</th>
<th>Warning</th>
<th>Time to Withdrawal in Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azaribine</td>
<td>Dermatologic (psoriasis)</td>
<td>January 1, 1975</td>
<td>Thromboembolism</td>
<td>2.4</td>
</tr>
<tr>
<td>Ticrynafen</td>
<td>Antihypertensive</td>
<td>May 2, 1979</td>
<td>Hepatic toxicity</td>
<td>0.7</td>
</tr>
<tr>
<td>Zomepirac sodium</td>
<td>Analgesic, nonsteroidal anti-inflammatory</td>
<td>October 28, 1980</td>
<td>Anaphylaxis</td>
<td>2.3</td>
</tr>
<tr>
<td>Benoxaprofen</td>
<td>Analgesic, nonsteroidal anti-inflammatory</td>
<td>April 19, 1982</td>
<td>Jaundice</td>
<td>0.3</td>
</tr>
<tr>
<td>Suprofen</td>
<td>Analgesic, nonsteroidal anti-inflammatory</td>
<td>December 24, 1984</td>
<td>Flank pain syndrome</td>
<td>1.3</td>
</tr>
<tr>
<td>Nomifensine maleate</td>
<td>Antidepressant</td>
<td>December 31, 1984</td>
<td>Hemolytic anemia</td>
<td>1.4</td>
</tr>
<tr>
<td>Terfenadine†</td>
<td>Antihistamine</td>
<td>May 8, 1985</td>
<td>Drug interactions causing cardiotoxicity</td>
<td>12.8</td>
</tr>
<tr>
<td>Encainide hydrochloride†</td>
<td>Antihypothalamic</td>
<td>December 24, 1986</td>
<td>Increased mortality in patients with asymptomatic ventricular arrhythmias</td>
<td>5.0</td>
</tr>
<tr>
<td>Astemizole†</td>
<td>Antihistamine</td>
<td>December 29, 1988</td>
<td>Drug interactions</td>
<td>10.5</td>
</tr>
<tr>
<td>Temafloxicin hydrochloride</td>
<td>Fluoroquinolone antibiotic</td>
<td>January 30, 1992</td>
<td>Hemolytic anemia</td>
<td>0.3</td>
</tr>
<tr>
<td>Flosequinan</td>
<td>Congestive heart failure</td>
<td>December 30, 1992</td>
<td>Hypoglycemia in elderly patients</td>
<td>0.3</td>
</tr>
<tr>
<td>Cisapride†</td>
<td>Acid/peptic disorders</td>
<td>July 29, 1993</td>
<td>Renal failure</td>
<td>0.3</td>
</tr>
<tr>
<td>Troglitazone†</td>
<td>Blood glucose regulator</td>
<td>January 29, 1997</td>
<td>Abnormal liver test results</td>
<td>0.3</td>
</tr>
<tr>
<td>Mibefradil dihydrochloride</td>
<td>Antihypertensive calcium-channel blocker</td>
<td>June 20, 1997</td>
<td>Coagulopathy</td>
<td>0.3</td>
</tr>
<tr>
<td>Bromfenac sodium</td>
<td>Analgesic, nonsteroidal anti-inflammatory</td>
<td>July 15, 1997</td>
<td>Hepatic failure</td>
<td>1.0</td>
</tr>
<tr>
<td>Grepafloxacin hydrochloride</td>
<td>Fluoroquinolone antibiotic</td>
<td>November 6, 1997</td>
<td>Cardiovascular events</td>
<td>2.0</td>
</tr>
</tbody>
</table>

*All drugs were approved between 1975 and 1999. †Drug had a Physicians’ Desk Reference black box warning prior to withdrawal.
patic, hematologic, or cardiac toxicity. Clinicians should report ADRs to MEDWATCH, the voluntary reporting system. Given the inadequacy of clinician reporting of ADRs, other reporting methods such as patient-initiated reporting should be explored. Innovative new therapies are important, but when safe and effective therapies already exist, any new drug should be considered a black box.


Funding/Support: Dr Lasser's work was supported by National Research Service Award grant ST32PE11001-12, and Drs Woolhandler and Himmelstein's work was supported in part by a grant from the Open Society Institute.

Acknowledgment: Sidney S. Atwood, BA, provided assistance in programming and data management; Peg Hewitt, research librarian, and the Tufts Center for the Study of Drug Development made their data on drugs approved in the United States available to us; John Orav, PhD, helped with statistical analyses; Larry D. Saisch, PharmD, MPH, provided us with additional information on specific drugs; and Maxim D. Shrayder, PhD, commented on earlier drafts of the manuscript.

REFERENCES


41. Additions to the list of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Available at: http://www.fda.gov/cder/damda/pcwclist.txt. Accessed August 13, 2001.


